Matthew Bowden

Company Secretary · AstraZeneca

Pharmaceuticals

Matthew Bowden is AstraZeneca’s company secretary. He previously served as deputy company secretary and became secretary of AstraZeneca PLC in May 2025.

Last reviewed: Nov 16, 2026

Executive Summary

Matthew Bowden is AstraZeneca’s company secretary. He previously served as deputy company secretary and became secretary of AstraZeneca PLC in May 2025.

Career Highlights

  • Appointed AstraZeneca PLC company secretary on May 1, 2025.
  • Earlier SEC filings identify him as deputy company secretary.
  • Signed the company’s November 2, 2026 securities notification.

Professional Journey

Bowden worked as deputy company secretary at AstraZeneca before taking the group company-secretary office. In February 2020, he also served as a director of MedImmune Limited, a group subsidiary.

He became secretary of AstraZeneca PLC on May 1, 2025. The same day, he also became secretary of AstraZeneca UK Limited, the operating subsidiary where he had held his earlier deputy-secretary position.

His company-secretary work includes regulatory notifications concerning AstraZeneca securities. On November 2, 2026, he signed its notification covering the admission to London trading of shares issued under employee share schemes during October.

Education

No institution-specific degree entry is listed.